Overview

The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy
Phase:
Phase 3
Details
Lead Sponsor:
Herlev and Gentofte Hospital
Treatments:
Interleukin 1 Receptor Antagonist Protein